APTO - Aptose Biosciences Inc.

1.71
-1.440   -84.211%

Share volume: 670,384
Last Updated: 04-01-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.19%

PREVIOUS CLOSE
CHG
CHG%
$3.15
-1.44
-0.46%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 35%
Dept financing 42%
Liquidity 47%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
829.35%
1 Year
313.04%
2 Year
-54.88%
Key data
Stock price
$1.71
P/E Ratio 
0.00
DAY RANGE
$1.35 - $1.99
EPS 
-$5.68
52 WEEK RANGE
$0.11 - $3.98
52 WEEK CHANGE
$274.18
MARKET CAP 
8.040 M
YIELD 
N/A
SHARES OUTSTANDING 
2.552 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
02-26-2025
NEXT EARNINGS DATE
06-27-2025
BETA 
-0.03
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: William G. Rice
Region: US
Website: aptose.com
Employees: 40
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Aptose Biosciences discovers and develops personalized therapies addressing unmet medical needs in oncology. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and HR MDS. The company also develops luxeptinib, a dual bromodomain and extra-terminal domain motif motif motif protein and kinase inhibitor program.

Recent news